BOOKS BY CATEGORY
Your Account
Re-Engineering Clinical Trials
Best Practices for Streamlining the Development Process
This book is currently unavailable – please contact us for further information.
Price
Quantity
€106.08
(To see other currencies, click on price)
Paperback / softback
Add to basket  

MORE ABOUT THIS BOOK

Main description:

Re-Engineering Clinical Trials evaluates the trends and challenges associated with the current drug development process and presents solutions that integrate the use of modern technologies and novel study designs. The pharmaceutical industry is currently operating under a business model that is not sustainable for the future. Given the high costs associated with drug development, there is a vital need to reform this process in order to provide safe and effective drugs while still securing a profit. More focus on rare diseases and personalized medicines increase the need for more efficient processes. This book focuses on the need to simplify drug development and offers well-established methodologies and best practices based on real-world experiences from expert authors across industry and academia. The second edition is completely updated, including new sections on Patient Centricity, Machine Learning, Bayesian Statistics, Disruption in R&D, Wearable technologies, Virtual trials, Real World Evidence, Operational Analytics. Written for all those involved in clinical research, development and clinical trial design, this book provides a unique and valuable resource for streamlining the process, containing costs and increasing drug safety and effectiveness.


Contents:

Section 1: Why Does the Industry Need a Change? 1. Why is our industry struggling? 2. What are the current main obstacles to reach drug approval? 3. Japan: An opportunity to learn? 4. The "Clinical Trial App"

Section 2: What Does Our Industry and What Do Others Do 5. What does "re-engineering" mean in our industry? 6. How can the Innovative Medicines Initiative help to make drug development more efficient? 7. Experiences with Lean and Shopfloor Management in R&D in other branches 8. Well-known methodologies, but not in our world: FMEA

Section 3: Where to Start: The Protocol 9. No patients, no data: Patient recruitment in the 21st century 10. The impact of bad protocols 11. Data mining for better protocols 12. It is all in the literature 13. What makes a good protocol better? 14. The Clinical Trial Site

Section 4: Alternative Study Designs 15. Do we need new endpoints? Surrogate and bio-marker 16. On the measurement of the disease status in clinical trials: lessons from MS 17. Generating evidence from historical data using "robust prognostic matching": Experience from Multiple Sclerosis 18. Studies with fewer patients involved: the Adaptive Trial 19. Studies with less site involvement: the Hyper Trial 20. Studies without sites: the Virtual Trial

Section 5: From Data to Decisions 21. Data standards against data overload 22. Data management 2.0 23. What do Sites Want? 24. From data to information and decision: ICONIK 25. Knowledge Management 26. Taking Control of Ever Increasing Volumes of Unstructured Data 27. Share the Knowledge based on quality data

Section 6: You Need Processes, Systems and People 28. It's all about the people (and their competencies) 29. Manage the Change 30. How Key Performance Indicators help to manage the change

Conclusions


PRODUCT DETAILS

ISBN-13: 9780128204894
Publisher: Elsevier (Academic Press Inc)
Publication date: March, 2023
Pages: 360
Weight: 652g
Availability: Not available (reason unspecified)
Subcategories: General Issues, Pharmacology

CUSTOMER REVIEWS

Average Rating